Ironwood Pharmaceuticals Receives FDA Orphan Drug Designation for Olinciguat
Ironwood Pharmaceuticals Inc. (IRWD) announced on June 7 that the FDA granted Orphan Drug Designation to Olinciguat (IW-1701) for patients with sickle cell disease. The FDA grants orphan status to drugs that are intended to treat rare disorders that affect fewer than 200,000 patients in the United States. The designation gives the developer fee waivers […]